Additional file 1 of Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Foss-Freitas, Maria C.; Akinci, Baris; Neidert, Adam; Bartlett, Victoria J.; Hurh, Eunju; Karwatowska-Prokopczuk, Ewa; Oral, Elif A.

doi:10.6084/m9.figshare.17127352.v1

12944_2021_1589_MOESM1_ESM.docx (15.7 kB)

Additional file 1 of Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

journal contribution

posted on 2021-12-06, 04:17 authored by Maria C. Foss-Freitas, Baris Akinci, Adam Neidert, Victoria J. Bartlett, Eunju Hurh, Ewa Karwatowska-Prokopczuk, Elif A. Oral

Additional file 1.

Funding

akcea therapeutics

History

Usage metrics

Keywords

Familial partial lipodystrophy Angiopoietin-like protein 3 Triglycerides Mixed meal test Adipose tissue insulin resistance Vupanorsen

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Funding

akcea therapeutics

History

Usage metrics

Categories

Keywords

Licence

Exports